Viking Therapeutics is progressing well with its obesity drug pipeline, focusing on a unique dual agonist treatment in a competitive market dominated by Lilly and Novo Nordisk. The company targets capturing 5–10% of the market through global expansion and late-stage development, with Phase 3 trials for its oral drug VK2735 expected by late 2026. Commercial launch is anticipated in 2028, potentially generating $1.3 billion in sales by 2030. Despite concerns over cash burn, investor confidence remains strong, with consistent buying since April 2025 indicating optimism about the company's growth prospects.
The Dow Jones reached a record high of 50,579.70 while the S&P 500 logged its eighth consecutive weekly gain despite consumer sentiment hitting a record low. Brent crude oil remains above $103 per barrel due to supply risks around the Strait of Hormu...
BioLineRx, a clinical-stage biopharmaceutical company, will release its Q1 2026 financial results on May 27, 2026. Analysts expect an earnings loss of $1.04 per share and revenue of $343,000, reflecting ongoing development costs typical for its growt...
Google Cloud Security used the Instruqt platform to train over 150 professionals on Agentic AI during the Google Next 2026 conference. Each participant worked in a dedicated Google Cloud Vertex AI environment to build and explore AI agents hands-on, ...
At Google Next 2026, Google Cloud Security used the Instruqt platform to train over 150 practitioners on Agentic AI. Each participant received a dedicated Vertex AI environment to build their own AI agents hands-on, moving beyond slide-based demos. T...
At Google Next 2026, Google Cloud Security used the Instruqt platform to train over 150 professionals in agentic AI capabilities. Each participant received a dedicated Google Cloud Vertex AI environment to build and explore AI agents hands-on, moving...
